Immunity
Volume 50, Issue 2, 19 February 2019, Pages 477-492.e8
ArticleClonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Under an Elsevier user license
open archive
Graphical Abstract
Keywords
cancer
immunotherapy
IFN-γ
activation-induced cell death
anti-CTLA-4
anti-PD-1
Cited by (0)
- 6
Present address: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
- 7
Present address: Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
- 8
Present address: Amgen, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
- 9
Present address: Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
- 10
Lead Contact
© 2019 Elsevier Inc.